Candel Therapeutics Inc Stock
Candel Therapeutics Inc Stock price
Key metrics
| Market capitalization | $296.11m |
| Enterprise Value | $214.85m |
| P/E (TTM) P/E ratio | negative |
| EV/FCF (TTM) EV/FCF | negative |
| P/B ratio (TTM) P/B ratio | 3.90 |
| Revenue (TTM) Revenue | $0.00 |
| EBIT (operating result TTM) EBIT | $-33.60m |
| Free Cash Flow (TTM) Free Cash Flow | $-27.21m |
| Cash position | $92.17m |
Is Candel Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.
Candel Therapeutics Inc Stock Analysis
Analyst Opinions
4 Analysts have issued a Candel Therapeutics Inc forecast:
Analyst Opinions
4 Analysts have issued a Candel Therapeutics Inc forecast:
Financial data from Candel Therapeutics Inc
| Mar '25 |
+/-
%
|
||
| Revenue | - - |
-
|
|
| Gross Profit | -0.98 -0.98 |
16%
16%
|
|
| EBITDA | -33 -33 |
8%
8%
|
EBIT (Operating Income) EBIT | -34 -34 |
8%
8%
|
| Net Profit | -40 -40 |
6%
6%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Candel Therapeutics Inc directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Candel Therapeutics Inc Stock News
Company Profile
Candel Therapeutics, Inc. operates as a biopharmaceutical company that develops and commercializes cancer immunotherapy drugs. It offers aglatimagene besadenovec (CAN-2409), a replication-deficient adenovirus that delivers within infected cancer cells the herpes simplex virus thymidine kinase (HSV-tk) gene. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.
| Head office | United States |
| CEO | Paul-Peter Tak |
| Employees | 38 |
| Founded | 2002 |
| Website | www.candeltx.com |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
